3-溴-1H-吲唑-6-羧酸甲酯 | 192945-56-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 3-溴-1H-吲唑-6-羧酸甲酯
• 中文别名: 3-溴吲唑-6-甲酸甲酯
• 英文名称: methyl 3-bromo-1H-indazole-6-carboxylate
• 英文别名: methyl 3-bromo-2H-indazole-6-carboxylate
• CAS: 192945-56-5
• 化学式: C₉H₇BrN₂O₂
• 分子量: 255.071
• InChiKey: NXMJEXMODINMIJ-UHFFFAOYSA-N

物化性质

• 沸点：
  399.7±22.0 °C(Predicted)
• 密度：
  1.709±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  储存条件：2-8℃，请置于干燥处并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-bromoindazole-6-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-bromoindazole-6-carboxylate
CAS number: 192945-56-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7BrN2O2
Molecular weight: 255.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-1H-吲唑-6-羧酸甲酯 在 N-甲基吗啉 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 copper(l) iodide 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium t-butanolate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 叔丁醇 为溶剂， 反应 4.08h， 生成 N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-3-(morpholin-4-yl)-1-(thiophen-3-yl)-1H-indazole-6-carboxamide
  参考文献：
  名称：

  P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

  摘要：

  公开号：

  EP2411001B1
• 作为产物：
  描述：

  1H-吲唑-6-羧酸甲酯 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以91 %的产率得到3-溴-1H-吲唑-6-羧酸甲酯
  参考文献：
  名称：

  含三氮唑稠环类衍生物、药物组合物及其制备方法和应用

  摘要：

  本发明涉及含三氮唑稠环类衍生物、其药物组合物及其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为NK‑3受体拮抗剂，在治疗和/或预防一系列广泛的CNS和外周疾病等疾病或病症的用途，其中通式(I)中的各取代基与说明书中的定义相同。

  公开号：

  CN115260180A

文献信息

• [EN] SUBSTITUTED INDOLE MCL-1 INHIBITORS<br/>[FR] INHIBITEURS D'INDOLES MCL-1 SUBSTITUÉS
  申请人：UNIV VANDERBILT

  公开号：WO2017152076A1

  公开（公告）日：2017-09-08

  The present disclosure provides for compounds that inhibit the activity of an anti- apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over- expression or dysregulation of Mcl-1 protein.

  本公开提供了抑制抗凋亡Bcl-2家族成员髓细胞白血病-1（Mcl-1）蛋白活性的化合物。本公开还提供了用于治疗由Mcl-1蛋白过度表达或失调所特征的疾病和病况（例如癌症）的药物组合物以及使用化合物的方法。
• Compounds as syk kinase inhibitors
  申请人：Almirall, S.A.

  公开号：EP2489663A1

  公开（公告）日：2012-08-22

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

  本发明涉及一种化合物（I）的公式，以及制备这种化合物的方法，以及它们在治疗病理状况或疾病中的应用，这些病理状况或疾病容易通过抑制Syk激酶而得到改善。
• [EN] INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)<br/>[FR] COMPOSÉS INDOLIQUES OU ANALOGUES DE CEUX-CI UTILES DANS LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE (DMLA)
  申请人：NOVARTIS AG

  公开号：WO2012093101A1

  公开（公告）日：2012-07-12

  The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式(I)的化合物：一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
• 钠通道阻滞剂
  申请人：山东轩竹医药科技有限公司

  公开号：CN111825595A

  公开（公告）日：2020-10-27

  本发明属于医药领域，具体涉及如式(I)所示的化合物、其药学上可接受的盐、其溶剂化合物或其异构体，含有所述化合物、其药学上可接受的盐、溶剂化合物或异构体的药物组合物，制备所述化合物、其药学上可接受的盐、溶剂化合物或异构体的方法，以及所述化合物、其药学上可接受的盐、溶剂化合物或异构体在制备药物中的应用，所述药物用于治疗和/或预防受试者的与Nav1.7通道相关的疾病。
• Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na_V1.7 Inhibitors for the Treatment of Pain
  作者：Guanglin Luo、Ling Chen、Amy Easton、Amy Newton、Clotilde Bourin、Eric Shields、Kathy Mosure、Matthew G. Soars、Ronald J. Knox、Michele Matchett、Rick L. Pieschl、Debra J. Post-Munson、Shuya Wang、James Herrington、John Graef、Kimberly Newberry、Digavalli V. Sivarao、Arun Senapati、Linda J. Bristow、Nicholas A. Meanwell、Lorin A. Thompson、Carolyn Dzierba

  DOI：10.1021/acs.jmedchem.8b01550

  日期：2019.1.24

  3-aryl-indazole derivatives were identified as potent and selective Nav1.7 inhibitors. Compound 29 was shown to be efficacious in the mouse formalin assay and also reduced complete Freund’s adjuvant (CFA)-induced thermal hyperalgesia and chronic constriction injury (CCI) induced cold allodynia and models of inflammatory and neuropathic pain, respectively, following intraperitoneal (IP) doses of 30 mg/kg

  3-芳基吲哚和3-芳基吲唑衍生物被确定为有效的和选择性的Na v 1.7抑制剂。化合物29在小鼠福尔马林测定中显示有效，并且在腹膜内（IP）后分别降低了完全弗氏佐剂（CFA）引起的热痛觉过敏和慢性收缩损伤（CCI）引起的冷痛觉过敏以及炎性和神经性疼痛模型剂量为30 mg / kg。观察到的功效可能与小鼠背根神经节暴露和Na V 1.7效价与29相关。